drugset / Trial / NCT06245330
A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of AST-001 administered as a single agent.
Timeline
- Start
- 2022-07-07
- Primary completion
- 2027-08-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AST-001 | Unknown | 5 mg/m2 | Intravenous |
| Subject | AST-001 | Unknown | 40 mg/m2 | Intravenous |